Alixer Nexgen Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
- Paid Up Capital ₹ 2.00 M
- Company Age 7 Months 14 Days
About Alixer Nexgen Therapeutics
Alixer Nexgen Therapeutics Limited (ANTL) is a Public Limited Indian Non-Government Company incorporated in India on 12 July 2024 ( seven months 14 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Paper Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Akhilesh Sharma, Madhurima Singh, Vikas Gupta, and One other member serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U21001MH2024PLC428703
- Company No.
428703
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Jul 2024
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Alixer Nexgen Therapeutics?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhilesh Sharma  | Director | 12-Jul-2024 | Current |
| Madhurima Singh | Whole-Time Director | 12-Jul-2024 | Current |
| Vikas Gupta | Director | 12-Jul-2024 | Current |
| Srinivas Singh | Whole-Time Director | 12-Jul-2024 | Current |
Financial Performance of Alixer Nexgen Therapeutics.
Enhance accessibility to Alixer Nexgen Therapeutics's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Alixer Nexgen Therapeutics?
Unlock access to Alixer Nexgen Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Alkem Laboratories LimitedMadhurima Singh and Srinivas Singh are mutual person
Prospera Ventures Private LimitedMadhurima Singh is a mutual person
- Maaiya Social Change Front Foundation
Madhurima Singh is a mutual person
- Alkem Foundation
Srinivas Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Alixer Nexgen Therapeutics?
Unlock and access historical data on people associated with Alixer Nexgen Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alixer Nexgen Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alixer Nexgen Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.